Annuncio • Aug 11
Natural Biocon (India) Limited to Report Q1, 2027 Results on Aug 14, 2026 Natural Biocon (India) Limited announced that they will report Q1, 2027 results on Aug 14, 2026 New Risk • Aug 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.1% per year over the past 5 years. Revenue is less than US$1m (₹25m revenue, or US$267k). Market cap is less than US$10m (₹123.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Board Change • Jul 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. MD & Chairman Arunkumar Prajapati was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jul 14
Natural Biocon (India) Limited Announces Directorate Resignations, Effective July 14, 2026 Natural Biocon (India) Limited held a meeting of the Board of Directors on July 14, 2026. The company accepted the resignation of Mrs. Tapasya Sheth from the Directorship of the Company with effect from July 14, 2026. The company accepted the resignation of Mrs. Minaben Shah from the Directorship of the Company with effect from July 14, 2026. Reported Earnings • May 11
Full year 2026 earnings released: ₹0.02 loss per share (vs ₹0.021 profit in FY 2025) Full year 2026 results: ₹0.02 loss per share (down from ₹0.021 profit in FY 2025). Net loss: ₹400.0k (down 190% from profit in FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Annuncio • Apr 22
Natural Biocon (India) Limited to Report Q4, 2026 Results on Apr 30, 2026 Natural Biocon (India) Limited announced that they will report Q4, 2026 results on Apr 30, 2026 New Risk • Feb 15
New major risk - Revenue and earnings growth Earnings have declined by 3.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.6% per year over the past 5 years. Revenue is less than US$1m (₹40m revenue, or US$442k). Market cap is less than US$10m (₹109.1m market cap, or US$1.20m). Reported Earnings • Feb 15
Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0.093 profit in 3Q 2025) Third quarter 2026 results: ₹0.02 loss per share (down from ₹0.093 profit in 3Q 2025). Net loss: ₹427.0k (down 117% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Annuncio • Feb 09
Natural Biocon (India) Limited to Report Q3, 2026 Results on Feb 13, 2026 Natural Biocon (India) Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Dec 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (₹43m revenue, or US$476k). Market cap is less than US$10m (₹108.0m market cap, or US$1.20m). Reported Earnings • Nov 20
Second quarter 2026 earnings released Second quarter 2026 results: ₹0.02 loss per share. Net loss: ₹437.0k (down 122% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Annuncio • Nov 05
Natural Biocon (India) Limited to Report First Half, 2026 Results on Nov 12, 2025 Natural Biocon (India) Limited announced that they will report first half, 2026 results on Nov 12, 2025 Annuncio • Sep 09
Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2025 Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2025, at 12:30 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2026 earnings released First quarter 2026 results: EPS: ₹0.05. Revenue: ₹16.7m (up 69% from 1Q 2025). Net income: ₹1.39m (up 42% from 1Q 2025). Profit margin: 8.3% (down from 9.9% in 1Q 2025). The decrease in margin was driven by higher expenses. Annuncio • Aug 09
Natural Biocon (India) Limited to Report Q1, 2026 Results on Aug 13, 2025 Natural Biocon (India) Limited announced that they will report Q1, 2026 results on Aug 13, 2025 New Risk • Jun 13
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: ₹83m (US$969k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Revenue is less than US$1m (₹83m revenue, or US$969k). Market cap is less than US$10m (₹338.0m market cap, or US$3.92m). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Annuncio • May 17
Natural Biocon (India) Limited to Report Q4, 2025 Results on May 23, 2025 Natural Biocon (India) Limited announced that they will report Q4, 2025 results on May 23, 2025 New Risk • May 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Market cap is less than US$10m (₹305.0m market cap, or US$3.61m). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Revenue is less than US$5m (₹141m revenue, or US$1.7m). Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹10.43, the stock trades at a trailing P/E ratio of 73.1x. Average trailing P/E is 24x in the Consumer Retailing industry in India. Total returns to shareholders of 15% over the past three years. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. MD & Chairman Arunkumar Prajapati was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 27
Third quarter 2025 earnings released: EPS: ₹0.10 (vs ₹0.08 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.10 (up from ₹0.08 in 3Q 2024). Revenue: ₹12.8m (down 41% from 3Q 2024). Net income: ₹2.46m (up 161% from 3Q 2024). Profit margin: 19% (up from 4.3% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 11
Natural Biocon (India) Limited to Report Q3, 2025 Results on Feb 14, 2025 Natural Biocon (India) Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Buy Or Sell Opportunity • Jan 17
Now 20% undervalued Over the last 90 days, the stock has risen 12% to ₹13.03. The fair value is estimated to be ₹16.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Buy Or Sell Opportunity • Dec 30
Now 21% undervalued Over the last 90 days, the stock has risen 5.8% to ₹12.93. The fair value is estimated to be ₹16.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. New Risk • Dec 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Market cap is less than US$10m (₹404.0m market cap, or US$4.77m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Profit margins are more than 30% lower than last year (1.7% net profit margin). Revenue is less than US$5m (₹157m revenue, or US$1.9m). Annuncio • Nov 28
Natural Biocon (India) Limited announced that it expects to receive INR 469.35952 million in funding from Trendytactics Marketing Private Limited Natural Biocon (India) Limited announced a private placement that it will issue up to 33,525,680 equity shares of face value of INR 10 each share at an issue price of INR 14 per share for the gross proceeds of up to INR 469,359,520 on November 26, 2024. The transaction will include participation from Trendytactics Marketing Private Limited. The transaction has been approved by the board of directors of the company. Buy Or Sell Opportunity • Nov 12
Now 20% undervalued Over the last 90 days, the stock has risen 6.1% to ₹13.00. The fair value is estimated to be ₹16.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 114% over the last 3 years. Earnings per share has grown by 47%. Reported Earnings • Nov 10
Second quarter 2025 earnings released Second quarter 2025 results: EPS: ₹0.01. Revenue: ₹47.4m (up 46% from 2Q 2024). Net income: ₹2.02m (up 45% from 2Q 2024). Profit margin: 4.3% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annuncio • Nov 09
Natural Biocon (India) Limited to Report Q2, 2025 Results on Nov 09, 2024 Natural Biocon (India) Limited announced that they will report Q2, 2025 results on Nov 09, 2024 Annuncio • Sep 11
Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2024 Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time. Location: 1007, sankalp iconic, opp., vikram nagar,iscon temple cross, road,sg. highway,ahmedabad, gujarat-380054, gujarat India Reported Earnings • Aug 16
First quarter 2025 earnings released First quarter 2025 results: EPS: ₹0.01. Revenue: ₹9.87m (up 264% from 1Q 2024). Net income: ₹975.0k (up 83% from 1Q 2024). Profit margin: 9.9% (down from 20% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Annuncio • Aug 09
Natural Biocon (India) Limited to Report Q1, 2025 Results on Aug 14, 2024 Natural Biocon (India) Limited announced that they will report Q1, 2025 results on Aug 14, 2024 New Risk • Aug 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 127% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Market cap is less than US$10m (₹323.1m market cap, or US$3.86m). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (1.1% net profit margin). Revenue is less than US$5m (₹135m revenue, or US$1.6m). Annuncio • Jul 29
Natural Biocon (India) Limited announced that it has received INR 29.16 million in funding from Aarnah Capital Advisors Private Limited, Aventez Media & Technologies Ltd., Rich Pockets Online Services Limited, Satyasur Marketing Private Limited On July 27, 2024, Natural Biocon (India) Limited closed the transaction. The company issued 2,160,000 common shares at the price of INR 13.50 per common share for gross proceeds of INR 29,160,000. The transaction included participation from new investors Aarnah Capital Advisors Private Limited for 550,000 shares, Aventez Media & Technologies Ltd. for 300,000 shares, Rich Pockets Online Services Limited for 300,000 shares, Satyasur Marketing Private Limited for 100,000 shares, Premal Vaishnav for 10,000 shares. New Risk • Jul 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹172.7m market cap, or US$2.06m). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Profit margins are more than 30% lower than last year (1.1% net profit margin). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (₹135m revenue, or US$1.6m). New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹138.1m market cap, or US$1.65m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (1.1% net profit margin). Revenue is less than US$5m (₹135m revenue, or US$1.6m). Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹0.01 (vs ₹0.16 in FY 2023) Full year 2024 results: EPS: ₹0.01 (down from ₹0.16 in FY 2023). Revenue: ₹135.3m (up ₹122.8m from FY 2023). Net income: ₹1.53m (down 15% from FY 2023). Profit margin: 1.1% (down from 14% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹12.00, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 34x in the Trade Distributors industry in India. Total loss to shareholders of 23% over the past three years. Annuncio • May 19
Natural Biocon (India) Limited to Report Q4, 2024 Results on May 27, 2024 Natural Biocon (India) Limited announced that they will report Q4, 2024 results on May 27, 2024 Annuncio • Apr 18
Natural Biocon (India) Limited announced that it expects to receive INR 194.535 million in funding from Aarnah Capital Advisors Private Limited, Aventez Media & Technologies Limited, Copo Holdings Private Limited, MNDM Business Point Private Limited, Rich Pockets Online Services Private Limited, Satyasur Marketing Private Limited and another investor Natural Biocon (India) Limited announced a private placement of 1,44,10,000 Equity Shares of of INR 10 each face value at a price of INR 13.50 (including premium of INR 3.50) for a gross proceeds of INR 194,535,000 on April 16, 2024. The transaction includes participation from Aarnah Capital Advisors Private Limited for 2,500,000 shares, Aventez Media & Technologies Limited for 2,500,000 shares, Copo Holdings Private Limited for 2,500,000 shares, MNDM Business Point Private Limited for 2,500,000 shares, Rich Pockets Online Services Limited for 2,500,000 shares, Satyasur Marketing Private Limited for 2,000,000 shares and Premal Vaishnav for 10,000 shares. The transaction is subject to the approval of Shareholders in ensuing Extra Ordinary General Meeting and other statutory and regulatory approval and obtained approval from board of directors. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to ₹8.73, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 30x in the Trade Distributors industry in India. Total loss to shareholders of 44% over the past three years. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.04 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.08 (up from ₹0.04 in 3Q 2023). Revenue: ₹21.6m (up 456% from 3Q 2023). Net income: ₹941.0k (up 101% from 3Q 2023). Profit margin: 4.3% (down from 12% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹43m revenue, or US$521k). Market cap is less than US$10m (₹125.4m market cap, or US$1.51m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change). Annuncio • Feb 03
Natural Biocon (India) Limited to Report Q3, 2024 Results on Feb 12, 2024 Natural Biocon (India) Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹14.05, the stock trades at a trailing P/E ratio of 48.2x. Average trailing P/E is 27x in the Trade Distributors industry in India. Total loss to shareholders of 5.5% over the past three years. Reported Earnings • Nov 08
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: ₹32.4m (up ₹28.9m from 2Q 2023). Net income: ₹1.39m (up ₹1.20m from 2Q 2023). Profit margin: 4.3% (down from 5.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annuncio • Oct 25
Natural Biocon (India) Limited to Report Q2, 2024 Results on Nov 03, 2023 Natural Biocon (India) Limited announced that they will report Q2, 2024 results on Nov 03, 2023 Annuncio • Aug 27
Natural Biocon (India) Limited, Annual General Meeting, Sep 22, 2023 Natural Biocon (India) Limited, Annual General Meeting, Sep 22, 2023, at 15:00 Indian Standard Time. Location: A Boutique Hotel, Chimanlal Girdharlal Rd, Opp. Municipal Market, Vasant Vihar, Navrangpura Ahmedabad Gujarat India Agenda: To consider and adopt of the audited financial statements of the company for the financial year ended march 31, 2023 and the reports of the board of directors and auditors thereon; and to consider re-appointment of Mr. Arun kumar Prajapati as a director, who retires by rotation and being eligible, offers himself for re-appointment. New Risk • Aug 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (₹11m revenue, or US$129k). Market cap is less than US$10m (₹105.3m market cap, or US$1.27m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Annuncio • Aug 04
Natural Biocon (India) Limited to Report Q1, 2024 Results on Aug 12, 2023 Natural Biocon (India) Limited announced that they will report Q1, 2024 results on Aug 12, 2023 Reported Earnings • Feb 16
Third quarter 2023 earnings released: EPS: ₹0.04 (vs ₹0.012 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.04 (up from ₹0.012 in 3Q 2022). Revenue: ₹3.90m (up ₹3.37m from 3Q 2022). Net income: ₹468.0k (up 239% from 3Q 2022). Profit margin: 12% (down from 26% in 3Q 2022). The decrease in margin was driven by higher expenses. Annuncio • Feb 02
Natural Biocon (India) Limited to Report Q3, 2023 Results on Feb 13, 2023 Natural Biocon (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CFO & Director Manish Patel is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 13
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: ₹3.53m (up 167% from 2Q 2022). Net income: ₹192.0k (down 63% from 2Q 2022). Profit margin: 5.4% (down from 40% in 2Q 2022). The decrease in margin was driven by higher expenses. Annuncio • Nov 03
Natural Biocon (India) Limited to Report Q2, 2023 Results on Nov 11, 2022 Natural Biocon (India) Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹5.10, the stock trades at a trailing P/E ratio of 77.6x. Average trailing P/E is 24x in the Trade Distributors industry in India. Total loss to shareholders of 75% over the past year. Annuncio • Sep 02
Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2022 Natural Biocon (India) Limited, Annual General Meeting, Sep 30, 2022. Location: 1007, Sankalp Iconic, Opp. Vikram Nagar, Iscon Temple Cross Road, S. G. Highway Ahmedabad Ahmedabad India Annuncio • Jul 28
Natural Biocon (India) Limited to Report Q1, 2023 Results on Aug 02, 2022 Natural Biocon (India) Limited announced that they will report Q1, 2023 results on Aug 02, 2022 Annuncio • May 28
Natural Biocon (India) Limited Announces Management Changes Natural Biocon (India) Limited announced that Ms. Birva Patel has assumed the office of Company Secretary and Compliance Officer with effect from May 27, 2022, in place of Mr. Prakhar Dubey, who resigned from the services of the Company on May 16, 2022. Annuncio • May 18
Natural Biocon (India) Limited Announces Resignation of Prakhar Dubey from the Post of Company Secretary & Compliance Officer with Effect from May 16, 2022 Natural Biocon (India) Limited announced resignation of Prakhar Dubey from the post of Company Secretary & Compliance Officer with effect from May 16, 2022. Annuncio • May 03
Natural Biocon (India) Limited to Report Q4, 2022 Results on May 16, 2022 Natural Biocon (India) Limited announced that they will report Q4, 2022 results on May 16, 2022 Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). CFO & Director Manish Patel is the most experienced director on the board, commencing their role in 2021. Additional Independent Director Suryakant Lohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.012. Net income: ₹138.0k (down 83% from 3Q 2021). Revenue was in line with analyst estimates. Annuncio • Feb 05
Natural Biocon (India) Limited to Report Q3, 2022 Results on Feb 10, 2022 Natural Biocon (India) Limited announced that they will report Q3, 2022 results on Feb 10, 2022 Board Change • Jan 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CFO, MD & Director Manish Patel is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. CFO, MD & Director Manish Patel is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Jigishaben Shah is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 12
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Jigishaben Shah was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Jigishaben Shah was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 14
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Jigishaben Shah was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Jigishaben Shah was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Executive Departure • Aug 10
Company Secretary & Compliance Officer Sushil Gond has left the company On the 4th of August, Sushil Gond's tenure as Company Secretary & Compliance Officer ended. We don't have any record of a personal shareholding under Sushil's name. Sushil is the only executive to leave the company over the last 12 months. Annuncio • Feb 01
Natural Biocon (India) Limited to Report Q3, 2021 Results on Feb 06, 2021 Natural Biocon (India) Limited announced that they will report Q3, 2021 results on Feb 06, 2021 Annuncio • Aug 16
Natural Biocon (India) Limited to Report Q1, 2021 Results on Aug 25, 2020 Natural Biocon (India) Limited announced that they will report Q1, 2021 results on Aug 25, 2020 
